Uniqure NV Investors Conference Call Transcript
Good day, and thank you for standing by. Welcome to uniQure's AMT-130 Huntington's Disease Program Update. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker to Maria Cantor, Chief Corporate Affairs Officer. Please go ahead.
Good morning, and thank you for joining us. This morning, uniQure announced safety and biomarker data on 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 in Huntington's disease.
6 of these 10 patients received AMT-130 and 4 patients experienced an imitation surgical procedure in this randomized blinded study being conducted in the United States. Observations shared today pertain to safety, tolerability and biomarker data at 12 months following AMT-130 administration.
Joining me for this investor event and webcast are Matt Kapusta, our Chief Executive Officer; and Dr. Ricardo Dolmetsch, our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |